224 results about "Depressed - symptom" patented technology

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of artificial intelligence, and discloses an interpretable depression detection method and system, and the method comprises the steps: retrieving a post related to a depressive symptom from a user social media history; on the basis of the post text corresponding to the symptom problem, a problem perception text representation is generated through fusion of a Longform encoder and an attention mechanism, and an optimal reasoning strategy is selected from a predefined reasoning strategy pool through a hybrid expert network; based on an inference strategy of question perception text representation and selection, selecting a most adaptive large language model from a predefined large language model pool through a hybrid expert network; deducing the severity of each depression symptom of the user according to an inference strategy and a large language model, and calculating the overall depression symptom severity of the user; according to the method, the reasoning strategy and the large language model are dynamically selected through the hybrid expert network, the optimal processing combination is adaptively matched for different symptom features and post contents, and the limitation of a fixed reasoning mode is overcome.

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The invention belongs to the technical field of medical application, and particularly relates to application of neomangiferin in preparation of an anti-depression drug, experiments find that the effect of neomangiferin is obviously better than that of mangiferin, although the neomangiferin and the mangiferin have the same main structure, the inventor finds that the effects of the neomangiferin and the mangiferin have obvious difference, and the effect of the neomangiferin and the mangiferin is obviously different. The compound is unexpected by the inventor before experiments, a new optional medicine is provided for research and development of anti-depression, and the effect of the anti-depression medicine is effectively improved.

The invention discloses application of a combination of probiotics GOLDGUT-M520 and GOLDGUT-LR99 in preparation of a product for relieving depression, and belongs to the technical field of biological medicines. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

To provide an AI system capable of estimating severity of dementia and / or depression in a subject on the basis of information obtained outside a hospital.SOLUTION: A method of creating teacher data for an AI system for estimating severity of dementia and / or depression is provided. Information to be used as teacher data for the AI system can be acquired from a site where a user receives prescribed drugs or from an application on a mobile terminal used by the user. The teacher data at least includes a face picture of the user, and a prescription, instruction, or information that enables estimation of dementia and / or depression in the user.SELECTED DRAWING: Figure 1

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1

The invention discloses a related product of FT3 in depression risk assessment and application, and relates to the field of depression diagnosis. The marker provided by the invention comprises FT3 and shows a remarkable technical effect in the aspect of predicting depression, high-precision early recognition and risk prediction of depression are realized, a key window and an objective basis are provided for early active intervention and whole-course management of diseases, and the accuracy and reliability of screening and diagnosis are greatly improved. Meanwhile, the marker has excellent universality, is suitable for wide population screening, and lays a technical foundation for low-cost and high-efficiency large-scale depression screening. In conclusion, a brand new technical means is provided for effective diagnosis and risk early warning of depression, and the industrial application prospect is wide.

The present invention relates to a method for the differential diagnosis of bipolar versus unipolar disorder in a human patient during a depressive phase from a biological sample of the patient, comprising determining the relative proportions of RNA editing variants of at least the A-to-I-edited RNA ZNF267 gene. The present invention also relates to a method for monitoring the treatment of a depressed patient exhibiting bipolar or unipolar disorder. Finally, the present invention provides a kit for the differential diagnosis of bipolar versus unipolar disorder in a patient during a depressive phase.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

The invention discloses application of micromolecule RNA in preparation of a medicine for treating depression, and belongs to the technical field of biomedicine. The invention finds that the small molecule RNA comprising the nucleotide sequence shown as ACAUUCA has a remarkable anti-depression effect. The micromolecule RNA, especially miR-181a-5p, acts on a chronic social contusion stress (CSDS) model mouse of which the expression level of the mPFC brain region is remarkably reduced, and the miR-181a-5p level of the mPFC brain region of the CSDS model mouse can be improved, so that the pathological change and depression-like behaviors of the CSDS mouse can be remarkably improved. According to the application of the small-molecule RNA in preparation of the anti-depression medicine, the small-molecule RNA can recover mitochondrial functions of neurons in a CSDS model mouse mPFC brain region, repair neuronal synaptic injury and improve and recover depression-like behaviors of depression diseases.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The present disclosure relates to an apparatus and a method for managing depression in a perinatal period. The apparatus comprises: a memory that stores at least one instruction for managing depression in a perinatal period; and a processor that performs an operation according to the instruction, wherein the processor analyzes, through a cognitive therapy model, questionnaire information and speech information collected from a terminal of a mother, so as to identify negative thought patterns and emotions of the mother, and evaluates the mental health level of the mother according to the identified negative thought patterns and emotions, the cognitive therapy model learns a trigger keyword related to depression of the mother, and, when a word showing similarity greater than or equal to a preset level with the learned trigger keyword is detected from the questionnaire information or the speech information, the mental health level of the mother can be evaluated according to the analysis result of the detected keyword.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

FIELD: psychiatry; narcology.SUBSTANCE: used to stabilize remission of alcohol dependence in patients with comorbid depression. After the withdrawal state with alcohol dependence syndrome and comorbid depressive disorder has been relieved, the patient takes agomelatine orally at a dosage of 25 mg once a day daily for 12 weeks.EFFECT: method is accessible and allows for stabilizing remission in patients with alcohol dependence syndrome and depressive disorder.1 cl

The invention discloses application of plasma neuron-derived exosomes in depression diagnosis, the neuron-derived exosomes are extracted from plasma to detect NDEVs in serum and detect the USP11 level, and the USP11 level in the NDEVs of a depression patient is found to be significantly higher than that in a healthy control, so that the USP11 level in the NDEVs in the serum can reflect the biological state of an intracranial nerve cell state. The detection specificity and sensitivity can be remarkably improved in the diagnosis of depression, and the method has very high clinical application value.

Embodiments directed to a computer-implemented diagnostic system and method to determine various diagnoses for different users, as well as symptom severity and onset of conditions associated with such diagnoses are described. In one example, a computer-implemented method of diagnosing health conditions for users includes identifying a defined linguistic pattern in digital biomarker data of a user. The method further includes prompting the user to perform a defined screening test based at least in part on identifying the defined linguistic pattern. The method further includes monitoring linguistic performance of the user while the user performs the defined screening test. The method further includes determining a diagnosis for the user based at least in part on the defined linguistic pattern, the linguistic performance, and a test result for the user from the defined screening test.

The invention concerns methods for treating mood disorders such as depressive disorder or episodes, or other mood disorders with current depressive episodes, by administration of a leptin receptor agonist, such as metreleptin. The invention further shows amelioration of depressive disorder or episode and related conditions in patients suffering from depression as a primary disorder, or a depressive disorder or episode as a secondary disorder and / or comorbidity. The invention also concerns methods for treating a depressive episode, or a depressive disorder.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention discloses an application of schaftoside in preparation of an anti-depression drug, and it is found through research that schaftoside can relieve inflammatory response and neurotransmitter reduction in the brain and significantly improve mouse depression-like behaviors induced by chronic constraint stress, and has statistical significance. The schaftoside shows an obvious anti-depression effect and can be used for preparing the medicine for preventing or treating depression. According to the invention, the medicinal value of schaftoside is expanded, and meanwhile, a new drug choice is provided for prevention and treatment of depression.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

This invention relates to the field of depression treatment technology, and in particular to the application of Trillium truncatum extract in the preparation of drugs for treating depression. The extraction method of the Trillium truncatum extract includes the following steps: S1, adding ethanol solution to Trillium truncatum at a material-to-liquid ratio of 1:10-12, and refluxing at 80-90℃ to obtain an extract; S2, concentrating the extract once, then adding macroporous resin for elution to obtain an eluent; centrifuging, concentrating a second time, and freeze-drying the eluent to obtain the Trillium truncatum extract. In this invention, the use of Trillium truncatum extract as a drug for treating depression can significantly alleviate symptoms of depression and psychogenic depression in mice. Furthermore, since Trillium truncatum extract is a natural substance, it has no toxic side effects, and its price is far lower than existing Western medicines for treating depression, making it convenient for widespread application in the treatment of depression.

The invention discloses a novel application of Vanin-1 protein as a depression diagnosis biomarker as well as a related mechanism and application of the Vanin-1 protein, and particularly discloses that liver Vanin-1 deficiency is a core mechanism of depression attack, and a key function of the liver Vanin-1 deficiency is verified through functional experiments. Meanwhile, the invention discloses that the Vanin-1 protein in blood can be used as a molecular marker for diagnosing depression, and the reduction of the content of the Vanin-1 protein indicates the risk of depression.